Favipiravir Current Affairs - 2020

GoI decides against including Itolizumab in treating COVID-19

The National Task Force on COVID-19 recently decided against using Itolizumab in clinical management protocols. The Drugs Controller General of India (DCGI) had earlier approved for “restricted emergency use” of the drug. Highlights Itolizumab is used to treat psoriasis. It was recently approved for the treatment of cytokine release syndrome in ‘moderate’ to ‘severe’ acute Read More…

India’s First Oral Vaccine for Moderate COVID-19 Cases gets Approval

For the treatment of mild to moderate COVID-19 positive patients across the country, on 19th June 2020, for manufacturing and marketing of oral antiviral drug ‘Favipiravir (Fabiflu)’ was approved by the National Regulatory Authority for Indian pharmaceuticals -Central Drugs Standard Control Organisation (CDSCO) to Mumbai based Glenmark Pharmaceuticals. The approval for the drug was given Read More…